Arrowhead Pharmaceuticals (ARWR) FY2024 results: revenue $4 million, down 98.5% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $4 million for fiscal 2024, the year ended 30 September 2024, down 98.5% on the year before. Net income was -$599 million, and diluted earnings per share $-5.00. The figures are the company's own, from the 10-K it filed with the SEC on 26 November 2024.
Revenue
$4 million
-98.5% on the year
FY2017FY2024
Operating margin
-16927.1%
-85.2% a year earlier
FY2017FY2024
Net income
-$599 million
FY2017FY2024
Diluted EPS
-$5.00
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-463
-154
-136
Capital expenditure
141
177
52.8
-20.0%
Free cash flow
-604
-331
-189
Free cash flow margin
-17018.3%
-137.3%
-77.7%
Cash from investing
-420
-96.2
-5.4
Cash from financing
871
253
65.2
+244.0%
Depreciation and amortisation
16.9
10.7
8.7
+57.9%
Share-based compensation
74.0
78.1
121
-5.3%
Diluted shares, weighted
120m
107m
105m
+12.2%
Shares outstanding at period end
124m
107m
106m
+15.9%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
185
271
399
-31.7%
Non-controlling interest
5.6
15.8
19.8
-64.5%
Debt
393
0.0
0.0
Operating lease liabilities
111
105
78.8
+6.1%
Other liabilities
445
374
195
+18.9%
Total liabilities and equity
1,140
766
692
+48.9%
Fixed assets
386
290
110
+33.0%
Intangible assets
8.6
10.3
12.0
-16.6%
Investments
578
293
0.0
+97.5%
Cash and equivalents
103
111
108
-7.4%
Receivables
0.0
0.0
1.4
Other assets
64.2
61.4
460
+4.6%
Total assets
1,140
766
692
+48.9%
10-K for the year ended 30 September 2024, filed 26 November 2024: the filing.